|
|
HER2低表达乳腺癌的治疗现状及研究进展
|
Abstract:
在女性中，乳腺癌是最常确诊的癌症，也是癌症死亡的首要原因。人表皮生长因子受体2 (HER2)是明确的乳腺癌驱动基因，其扩增与肿瘤的发生和侵袭相关。研究表明，HER2低表达乳腺癌占全部类型的45%~55%，其生物学亚型及临床病理学特征有别于其他HER2分型表现出明显差异。在目前的临床实践中，仍有一部分HER2低表达被报告为HER2阴性或三阴性乳腺癌，其治疗策略未能满足精准治疗的需求。然而，随着新型抗体药物偶联物(Antibody-drug conjugates, ADC)在HER2低表达乳腺癌中显示出的显著疗效，HER2低表达这一概念逐渐走进人们的视野，其精准治疗时代或将到来。本文将对HER2低表达乳腺癌的研究现状及治疗进展进行综述。
Among women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-related deaths. Human epidermal growth factor receptor 2 (HER2) is an established driver gene for breast cancer, with its amplification linked to tumor onset and invasiveness. Studies indicate that breast cancers with low HER2 expression make up 45% to 55% of all types, and their biological subtypes and clinical-pathological features vary markedly from other HER2-type breast cancers. In present clinical practice, some cases of low HER2 expression are still reported as HER2-negative or triple-negative breast cancer, with treatment strategies falling short of precision therapy needs. However, the notable efficacy of new antibody drug conjugates (ADCs) in treating breast cancers with low HER2 expression has increasingly brought the concept of low HER2 expression into focus, signaling the potential advent of an era of precision treatment. This article provides a review of the current research status and therapeutic advancements in breast cancers with low HER2 expression.
| [1] | Swain, S.M., Miles, D., Kim, S., Im, Y., Im, S., Semiglazov, V., et al. (2020) Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA): End-of-Study Results from a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Study. The Lancet Oncology, 21, 519-530. https://doi.org/10.1016/s1470-2045(19)30863-0 |
| [2] | Shui, R., Liang, X., Li, X., Liu, Y., Li, H., Xu, E., et al. (2020) Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients from 19 Chinese Representative Clinical Centers. Clinical Breast Cancer, 20, e65-e74. https://doi.org/10.1016/j.clbc.2019.07.013 |
| [3] | Fehrenbacher, L., Cecchini, R.S., Geyer Jr., C.E., Rastogi, P., Costantino, J.P., Atkins, J.N., et al. (2020) NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy with or without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and with IHC 1+ or 2+. Journal of Clinical Oncology, 38, 444-453. https://doi.org/10.1200/jco.19.01455 |
| [4] | Wang, K., Zhou, S., Sun, Y., Yan, C., Wang, Y., Huang, X., et al. (2020) The Prognostic Significance of Wilms’ Tumor Gene 1 in Adult AML with Different Risk Stratification Following Allo-HSCT. Blood, 136, 4-5. https://doi.org/10.1182/blood-2020-139026 |
| [5] | 熊登宇, 汪贵林, 左怀全. HER-2低表达乳腺癌的临床病理特征及其对新辅助化疗反应[J]. 四川医学, 2022, 43(9): 878-884. |
| [6] | Yardley, D.A., Kaufman, P.A., Huang, W., Krekow, L., Savin, M., Lawler, W.E., et al. (2015) Quantitative Measurement of HER2 Expression in Breast Cancers: Comparison with ‘Real-World’ Routine HER2 Testing in a Multicenter Collaborative Biomarker Study and Correlation with Overall Survival. Breast Cancer Research, 17, Article No. 41. https://doi.org/10.1186/s13058-015-0543-x |
| [7] | Jensen, K., Krusenstjerna-Hafstrøm, R., Lohse, J., Petersen, K.H. and Derand, H. (2017) A Novel Quantitative Immunohistochemistry Method for Precise Protein Measurements Directly in Formalin-Fixed, Paraffin-Embedded Specimens: Analytical Performance Measuring HER2. Modern Pathology, 30, 180-193. https://doi.org/10.1038/modpathol.2016.176 |
| [8] | Ho-Pun-Cheung, A., Bazin, H., Boissière-Michot, F., Mollevi, C., Simony-Lafontaine, J., Landas, E., et al. (2019) Quantification of HER1, HER2 and HER3 by Time-Resolved Förster Resonance Energy Transfer in FFPE Triple-Negative Breast Cancer Samples. British Journal of Cancer, 122, 397-404. https://doi.org/10.1038/s41416-019-0670-8 |
| [9] | Wolff, A.C., Hammond, M.E.H., Allison, K.H., Harvey, B.E., Mangu, P.B., Bartlett, J.M.S., et al. (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 36, 2105-2122. https://doi.org/10.1200/jco.2018.77.8738 |
| [10] | 黄香, 蒋梦萍, 包胜南, 等. 2021年CSCO《乳腺癌诊疗指南》更新要点解读[J]. 中国肿瘤外科杂志, 2021, 13(3): 209-215. |
| [11] | Horisawa, N., Adachi, Y., Takatsuka, D., Nozawa, K., Endo, Y., Ozaki, Y., et al. (2021) The Frequency of Low HER2 Expression in Breast Cancer and a Comparison of Prognosis between Patients with HER2-Low and HER2-Negative Breast Cancer by HR Status. Breast Cancer, 29, 234-241. https://doi.org/10.1007/s12282-021-01303-3 |
| [12] | Tan, R.S.Y.C., Ong, W.S., Lee, K., Lim, A.H., Park, S., Park, Y.H., et al. (2022) HER2 Expression, Copy Number Variation and Survival Outcomes in HER2-Low Non-Metastatic Breast Cancer: An International Multicentre Cohort Study and TCGA-METABRIC Analysis. BMC Medicine, 20, Article No. 105. https://doi.org/10.1186/s12916-022-02284-6 |
| [13] | Won, H.S., Ahn, J., Kim, Y., Kim, J.S., Song, J., Kim, H., et al. (2022) Clinical Significance of HER2-Low Expression in Early Breast Cancer: A Nationwide Study from the Korean Breast Cancer Society. Breast Cancer Research, 24, Article No. 22. https://doi.org/10.1186/s13058-022-01519-x |
| [14] | Ergun, Y., Ucar, G. and Akagunduz, B. (2023) Comparison of HER2-Zero and HER2-Low in Terms of Clinicopathological Factors and Survival in Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis. Cancer Treatment Reviews, 115, Article ID: 102538. https://doi.org/10.1016/j.ctrv.2023.102538 |
| [15] | Yang, C., Zhang, X., Chen, Y., Li, P., Zhang, J., Xu, A., et al. (2023) Survival Differences between HER2-0 and HER2-Low-Expressing Breast Cancer—A Meta-Analysis of Early Breast Cancer Patients. Critical Reviews in Oncology/Hematology, 185, Article ID: 103962. https://doi.org/10.1016/j.critrevonc.2023.103962 |
| [16] | Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001) Use of Chemotherapy Plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine, 344, 783-792. https://doi.org/10.1056/nejm200103153441101 |
| [17] | Seidman, A.D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P.K., et al. (2008) Randomized Phase III Trial of Weekly Compared with Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, with Trastuzumab for All HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840. Journal of Clinical Oncology, 26, 1642-1649. https://doi.org/10.1200/jco.2007.11.6699 |
| [18] | Krop, I.E., LoRusso, P., Miller, K.D., Modi, S., Yardley, D., Rodriguez, G., et al. (2012) A Phase II Study of Trastuzumab Emtansine in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated with Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology, 30, 3234-3241. https://doi.org/10.1200/jco.2011.40.5902 |
| [19] | Doi, T., Shitara, K., Naito, Y., Shimomura, A., Fujiwara, Y., Yonemori, K., et al. (2017) Safety, Pharmacokinetics, and Antitumour Activity of Trastuzumab Deruxtecan (DS-8201), a HER2-Targeting Antibody-Drug Conjugate, in Patients with Advanced Breast and Gastric or Gastro-Oesophageal Tumours: A Phase 1 Dose-Escalation Study. The Lancet Oncology, 18, 1512-1522. https://doi.org/10.1016/s1470-2045(17)30604-6 |
| [20] | Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., et al. (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine, 387, 9-20. https://doi.org/10.1056/nejmoa2203690 |
| [21] | Li, H., Zhang, X., Xu, Z., Li, L., Liu, W., Dai, Z., et al. (2021) Preclinical Evaluation of MRG002, a Novel HER2-Targeting Antibody-Drug Conjugate with Potent Antitumor Activity against HER2-Positive Solid Tumors. Antibody Therapeutics, 4, 175-184. https://doi.org/10.1093/abt/tbab017 |
| [22] | Nordstrom, J.L., Gorlatov, S., Zhang, W., Yang, Y., Huang, L., Burke, S., et al. (2011) Anti-tumor Activity and Toxicokinetics Analysis of MGAH22, an Anti-HER2 Monoclonal Antibody with Enhanced Fcγ Receptor Binding Properties. Breast Cancer Research, 13, Article No. R123. https://doi.org/10.1186/bcr3069 |
| [23] | 王璐瑶, 魏振华, 熊伟佳, 等. 双特异性抗体构建在肿瘤临床治疗中的应用[J]. 生物工程学报, 2021, 37(2): 513-529. |
| [24] | Caruso, C. (2019) ZW25 Effective in HER2-Positive Cancers. Cancer Discovery, 9, Article No. 8. |
| [25] | Mittendorf, E.A., Lu, B., Melisko, M., Price Hiller, J., Bondarenko, I., Brunt, A.M., et al. (2019) Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. Clinical Cancer Research, 25, 4248-4254. https://doi.org/10.1158/1078-0432.ccr-18-2867 |
| [26] | Clifton, G.T., Hale, D., Vreeland, T.J., Hickerson, A.T., Litton, J.K., Alatrash, G., et al. (2020) Results of a Randomized Phase Iib Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer. Clinical Cancer Research, 26, 2515-2523. https://doi.org/10.1158/1078-0432.ccr-19-2741 |
| [27] | Brown, T.A., Mittendorf, E.A., Hale, D.F., Myers, J.W., Peace, K.M., Jackson, D.O., et al. (2020) Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of Two HER2 Peptide Vaccines, GP2 and AE37, in Breast Cancer Patients to Prevent Recurrence. Breast Cancer Research and Treatment, 181, 391-401. https://doi.org/10.1007/s10549-020-05638-x |
